JNJ - Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

2024-06-13 14:03:52 ET

Summary

• Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis.
• The global idiopathic pulmonary fibrosis market size is projected to reach $6.45 billion by 2031.
• The global multiple sclerosis drugs market size is projected to reach $38.94 billion by 2032.
• PIPE-307 is an M1R antagonist being developed for the treatment of other large, multibillion-dollar markets like RRMS and depression.

Contineum Therapeutics, Inc. ( CTNM ) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why investors should focus on this biotech is because it is advancing the use of its drug PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis [IPF] and progressive multiple sclerosis [PMS]. The phase 1 healthy volunteer study had already been completed and proved the drug to be safe and well tolerated. If this is the case, then what can investors expect in the coming months that could possibly cause the stock price to trade higher? Well, after the completion of the healthy volunteer phase 1 study, it is gearing up to initiate a phase 1b study. Such a study will be a PET scan study type, where cell activity of the lungs will be identified utilizing such a scan....

For further details see: